When patients stop taking popular weight loss medications like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), they don't necessarily regain all their lost weight. A major real-world study from Cleveland Clinic analyzed nearly 8,000 adults and found that many successfully stabilize their weight through alternative treatments and lifestyle interventions, contradicting earlier research suggesting dramatic weight rebound .

What Happened to Patients After They Stopped Their Medication?

Researchers at Cleveland Clinic's Center for Value-Based Care Research tracked patients who initiated injectable semaglutide or tirzepatide for obesity or type 2 diabetes and then stopped the medication within three to 12 months. The findings, published in the journal Diabetes, Obesity and Metabolism, revealed a more nuanced picture than previous clinical trials suggested .

For patients treated specifically for obesity, the results were encouraging. Those in the study lost an average of 8.4% of their body weight while taking the medication. After discontinuing the drug, they regained only an average of 0.5% one year later. Even more striking, 45% of the obesity group either kept losing weight or maintained their weight loss in the year after stopping medication .

The diabetes group showed even better outcomes. Patients treated for type 2 diabetes lost an average of 4.4% of body weight before stopping the medication, and then lost an additional 1.3% one year later. In this group, 56% continued losing weight or stayed the same after discontinuation .

"Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials," said Hamlet Gasoyan, a researcher with Cleveland Clinic's Center for Value-Based Care Research.

Hamlet Gasoyan, Researcher, Cleveland Clinic's Center for Value-Based Care Research

How Are Patients Managing Their Weight After Stopping These Drugs?

The key to understanding why weight regain wasn't as severe as expected lies in what patients did after stopping their initial medication. Rather than abandoning weight management entirely, most explored alternative approaches .

• Medication Switching: 27% of patients switched to a different weight loss medication, including older-generation obesity drugs or switching between semaglutide and tirzepatide to find a better option.
• Restarting Original Treatment: 20% of patients restarted their original GLP-1 medication after initially stopping it, suggesting they found the benefits worth continuing.
• Lifestyle-Based Support: 14% continued obesity treatment through lifestyle modification visits with healthcare professionals such as dietitians and exercise specialists.
• Surgical Intervention: Less than 1% transitioned to metabolic and bariatric surgery, indicating this remains a less common choice among those discontinuing medication.

These findings highlight an important reality: patients didn't simply give up on weight management when they stopped their initial medication. Instead, they pursued a variety of strategies to maintain their progress .

Why Did Patients Stop Taking These Medications in the First Place?

Understanding why patients discontinued their medications is crucial to interpreting the weight outcomes. Cleveland Clinic researchers identified two primary drivers: cost or insurance coverage limitations and side effects, with cost being the dominant reason .

Insurance coverage played a significant role in determining what happened next. Patients taking the drugs for diabetes were more likely to restart their medication compared with those using them for obesity. This difference was directly tied to more consistent insurance coverage for diabetes-related prescriptions, suggesting that financial barriers, rather than lack of effectiveness, often determine whether patients continue treatment .

The cost factor is particularly important because it reveals a gap between clinical trial settings and real-world practice. In randomized trials, patients typically have guaranteed access to medication for the duration of the study. In real life, insurance denials and out-of-pocket expenses force many patients to make difficult choices about continuing treatment, even if they're seeing results.

What Does This Mean for People Considering These Drugs?

The Cleveland Clinic study suggests that GLP-1 medications like semaglutide and tirzepatide may not be a temporary fix that leads to inevitable weight regain. Instead, they appear to be part of a longer-term weight management strategy that may include cycling on and off medication, switching between different treatments, or combining medication with lifestyle changes .

The research underscores the importance of personalized, ongoing support for patients seeking obesity treatment, even when they stop medication. Rather than viewing discontinuation as failure, both patients and clinicians should recognize it as a potential transition point where alternative strategies can be explored .

"Many patients do not give up on their obesity treatment journey, even if they need to stop their initial medication," noted Dr. Gasoyan. "In our future work, we will examine the comparative effectiveness of alternative treatment options for obesity in patients who discontinue semaglutide or tirzepatide, to help patients and their clinicians make informed decisions."

Hamlet Gasoyan, Researcher, Cleveland Clinic's Center for Value-Based Care Research

For individuals considering GLP-1 drugs, this study offers reassurance that stopping the medication doesn't automatically mean losing all progress. However, it also highlights the critical role that insurance coverage and cost play in treatment continuity. Those interested in these medications should have conversations with their healthcare providers about long-term treatment plans, potential alternatives if cost becomes an issue, and lifestyle strategies that can support weight maintenance regardless of medication status .